Aim for a deep molecular response—MR4.51
With TASIGNA, significantly more patients reached MR4.5 by 3 years and by 5 years, vs imatinib.1
Patients reached MR4.5 more than 1 year faster with TASIGNA, vs imatinib2
Nearly twice as many newly diagnosed patients reached MR4.5 more than 1 year faster with TASIGNA than with imatinib2
Patients achieved deeper responses faster with TASIGNA than with imatinib2
Across Sokal risk groups, TASIGNA achieved higher rates of MR4.5 than imatinib3
In ENESTnd, TASIGNA was superior to imatinib in all Sokal risk scores3
Percentage of patients with MMR by 1 year in ENESTnd1
Adverse events occurring at ≥10% in patients on TASIGNA: rash, pruritus, dry skin, headache, nausea, fatigue, alopecia, myalgia, constipation, and upper abdominal pain. Most were mild to moderate in severity (grade 1/2).1
ENESTnd is a randomized, controlled, open-label, international, multicenter trial of 846 patients with newly diagnosed Ph+ CML-CP. Patients were randomized to 1 of 2 TASIGNA arms or to imatinib. The primary endpoint was MMR at 12 months.1
- TASIGNA® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; May 2017.
- Larson RA, et al. Blood. 2014;124. Abstract 4541.
- Hochhaus A, et al. Leukemia. 2016;30(5):1044-1054.